Gene-disease association data could improve drug development

Drug development is a risky business. More than half of candidate drugs that look promising in the research lab will ultimately fail. More than a quarter of drugs that reach the clinical trial stage will be rejected as ineffective. June's Genome Advance of the Month focuses on how drug development success rates could be improved by using known genetic associations to help choose research targets.
Source: NHGRI Homepage Highlights - Category: Genetics & Stem Cells Source Type: news